Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.18908 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Luca Mastorino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
ORCID-Profile: Luca Mastorino, Pietro Quaglino, Simone Ribero
Zitieren
APA
Mastorino, L., Gelato, F., Richiardi, I., Cavaliere, G., Quaglino, P., Ortoncelli, M., & Ribero, S. (2023). Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18908
Vancouver
Mastorino L, Gelato F, Richiardi I, Cavaliere G, Quaglino P, Ortoncelli M, et al. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18908
BibTeX
@article{Mastorino2023,
author = {Mastorino, Luca and Gelato, Federica and Richiardi, Irene and Cavaliere, Giovanni and Quaglino, Pietro and Ortoncelli, Michela and Ribero, Simone},
title = {Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.18908}
}
EUVIMED